Mr. Speaker, the hon. member should know that this government and this department are very much concerned with drug safety. That is why, as I have indicated, we have put additional resources toward post-marketing surveillance so that in fact we can deal with incidents of adverse reaction.
I think the hon. member is probably also aware that last week a very important report was released in relation to patient safety. Only one part of patient safety is, of course, adverse reactions to drugs. My provincial-territorial colleagues and I are very committed to taking up the recommendations in and around patient safety and obviously adverse reactions to drugs will be part of that.